September 5, 2024 04:04 PM EDT

FDA raises antimicrobial resistance concerns ahead of adcomm for Iterum's UTI treatment

Nicole DeFeudis

Editor

The FDA has raised concerns about potential “inappropriate use” of Iterum’s oral candidate for uncomplicated urinary tract infections (uUTIs) ahead of a Monday advisory committee …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA raises antimicrobial resistance concerns ahead of adcomm for Iterum's UTI treatment

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

Updated: Bristol Myers touts LAG-3 strategy in lung cancer, but data caveats dampen excitement

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

FDA rais­es an­timi­cro­bial re­sis­tance con­cerns ahead of ad­comm for Iterum's UTI treat­ment

Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

FDA raises antimicrobial resistance concerns ahead of adcomm for Iterum's UTI treatment